Pfizer is currently trading at Rs. 1239.95, up by 40.50 points or 3.38% from its previous closing of Rs. 1199.45 on the BSE.
The scrip opened at Rs. 1227.00 and has touched a high and low of Rs. 1247.70 and Rs. 1210.00 respectively. So far 2349 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1636.20 on 28-Jul-2011 and a 52 week low of Rs. 1071.55 on 30-Dec-2011.
Last one week high and low of the scrip stood at Rs. 1247.70 and Rs. 1179.80 respectively. The current market cap of the company is Rs. 3700.34 crore.
The promoters holding in the company stood at 70.75% while Institutions and Non-Institutions held 9.01% and 20.24% respectively.
Pfizer has concluded the sale of animal health business to its wholly owned subsidiary - Pfizer Animal Pharma (PAPPL) for a consideration amount of Rs 440.00 crore, subject to any adjustments as determined under the business transfer agreement dated February 20, 2012 between the company and PAPPL.
Consequent to the closing of the transaction the animal health business comprising of, among other things, marketing and trading in drugs, formulations, vaccines, animal feeds and over-the-counter medications for animals, together with its rights, title and interest in the movable intangible and current assets but excluding its interest in land, buildings and property leases, along with its employees, assets and liabilities, stand transferred to PAPPL.
Earlier on February 06, 2012, the board of directors of Pfizer had approved the sale of its animal health division by way of a slump sale to PAPPL. Further, the shareholders of the company have by postal ballot approved the sale with requisite majority on March 26, 2012.
Pfizer, a subsidiary of Pfizer Inc, is engaged in manufacturing of products like Protinex, Isonex, Becosules and Corex.
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: